352 related articles for article (PubMed ID: 30968559)
1. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
Tijssen RYG; van der Schaaf RJ; Kraak RP; Vink MA; Hofma SH; Arkenbout EK; Weevers APJD; Kerkmeijer LSM; Onuma Y; Serruys PW; Beijk MAM; Koch KT; Baan J; Vis MM; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
Catheter Cardiovasc Interv; 2020 Jan; 95(1):89-96. PubMed ID: 30968559
[TBL] [Abstract][Full Text] [Related]
2. Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Kerkmeijer LSM; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Kraak RP; Onuma Y; Serruys PW; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
Catheter Cardiovasc Interv; 2021 Oct; 98(4):713-720. PubMed ID: 33118696
[TBL] [Abstract][Full Text] [Related]
3. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
Tijssen RYG; Kerkmeijer LSM; Katagiri Y; Kraak RP; Takahashi K; Kogame N; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MAM; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
Int J Cardiovasc Imaging; 2019 Jul; 35(7):1189-1198. PubMed ID: 30911857
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent - A Randomized Comparison Through 5 Years in Japan.
Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
[TBL] [Abstract][Full Text] [Related]
5. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
6. Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies.
Tarantini G; Masiero G; Barioli A; Paradies V; Vlachojannis G; Tellaroli P; Cortese B; di Palma G; Varricchio A; Ielasi A; Loi B; Steffenino G; Ueshima D; Mojoli M; Smits P
Catheter Cardiovasc Interv; 2018 Aug; 92(2):E115-E124. PubMed ID: 29513403
[TBL] [Abstract][Full Text] [Related]
7. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
8. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
[TBL] [Abstract][Full Text] [Related]
9. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
Kerkmeijer LSM; Renkens MPL; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Garcia-Garcia HM; Kraak R; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
EuroIntervention; 2022 Mar; 17(16):1340-1347. PubMed ID: 34483094
[TBL] [Abstract][Full Text] [Related]
12. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
[TBL] [Abstract][Full Text] [Related]
15. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
16. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
Zanchin C; Ueki Y; Zanchin T; Häner J; Otsuka T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Moschovitis A; Hunziker L; Valgimigli M; Pilgrim T; Heg D; Windecker S; Räber L
JACC Cardiovasc Interv; 2019 Sep; 12(17):1665-1675. PubMed ID: 31422088
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
[TBL] [Abstract][Full Text] [Related]
20. A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial.
Kerkmeijer LSM; Tijssen RYG; Hofma SH; Pinxterhuis TH; Kraak RP; Kalkman DN; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MA; Baan J; Vis MM; Koch KT; Tijssen JGP; Piek JJ; Henriques JPS; de Winter RJ; Wykrzykowska JJ
Int J Cardiol; 2020 Feb; 300():93-98. PubMed ID: 31511193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
